CLINICAL_TRIALS ClinicalTrials.gov record update

An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib "Sandwich"With Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03936452
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:36.931017+00:00
Published At: 2022-06-09T00:00:00+00:00
Record Updated At: 2022-06-09
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type", "Early Stage", "Anlotinib", "Peg-aspargase", "Sintilimab", "Phase Two", "Open", "Radiotherapy"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-06-09"
protocolSection.identificationModule.nctId: "NCT03936452"
protocolSection.identificationModule.officialTitle: "An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib \"Sandwich\"With Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.